Sosei : appoints Andrew Oakley as CFO

Sosei appoints Andrew Oakley as CFO Tokyo, Japan January 19 2017: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces the appointment of Andrew Oakley as Chief Financial Officer (CFO) effective from February 1 2017. Mr Oakley will be based in Sosei's Tokyo offices.

Mr Oakley will succeed Mr Hidetoshi Torami who has resigned from Sosei for personal reasons.

Mr Oakley, a Chartered Accountant with an MBA from London Business School, has had a wide and varied financial career and over the past 14 years has held CFO positions in several publicly listed biotechnology companies including Actelion Ltd, Novimmune SA, and most recently at Vectura Group plc, where he was also a member of the Board.

1. The name and title of new Chief Financial Officer Name: Andrew Oakley

   Title: Chief Financial Officer (CFO)

2. Brief summary of Andrew Oakley

   Date of birth	Profile	Ownership of shares of Sosei
   April 23, 1962	January 2003-August 2013: Executive Vice President & Chief Financial Officer (Actelion Pharmaceuticals Ltd.)	0
   	March 2014-November 2014: Chief Financial Officer (Novimmune SA)
   	January 2015-June 2016: Chief Financial Officer and Board Member (Vectura Group plc)

3. Effective date

As of February 1 2017

Commenting on the appointment, Peter Bains, CEO at Sosei, said: "Andrew brings a wealth of global corporate finance experience, expertise and leadership with a particularly strong focus in the biotechnology sector. I am delighted to welcome him to Sosei as our new CFO and look forward to working with Andrew in the coming years as we seek to build Sosei into a global presence'

-Ends-

Contact for Sosei

Harumi BANSE, Investor Relations

[phone]

[e-mail]

About Sosei

Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei have established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei have already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit www.sosei.com/en.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward- looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.